Libtayo (cemiplimab) vs Zepzelca (lurbinectedin)
Libtayo (cemiplimab) vs Zepzelca (lurbinectedin)
Libtayo (cemiplimab) is a type of immunotherapy known as a PD-1 inhibitor, used primarily for the treatment of certain types of skin cancers, such as advanced cutaneous squamous cell carcinoma, and has recently been approved for use in non-small cell lung cancer. Zepzelca (lurbinectedin) is a chemotherapy agent that works by interfering with the growth of cancer cells, and it is specifically indicated for the treatment of metastatic small cell lung cancer after prior platinum-based chemotherapy has failed. When deciding between these two medications, it is essential to consider the type of cancer being treated, as their indications and mechanisms of action are different, and a healthcare provider can offer guidance based on the individual's specific diagnosis and treatment history.
Difference between Libtayo and Zepzelca
| Metric | Libtayo (cemiplimab) | Zepzelca (lurbinectedin) |
|---|---|---|
| Generic name | Cemiplimab | Lurbinectedin |
| Indications | Cutaneous squamous cell carcinoma, Basal cell carcinoma, Non-small cell lung cancer | Small cell lung cancer |
| Mechanism of action | Programmed death receptor-1 (PD-1) blocking antibody | Trabectedin analog; binds to minor groove of DNA and inhibits transcription |
| Brand names | Libtayo | Zepzelca |
| Administrative route | Injection (IV) | Injection (IV) |
| Side effects | Fatigue, rash, diarrhea, musculoskeletal pain | Myelosuppression, fatigue, increased creatinine, hepatic enzyme increase |
| Contraindications | None known | None known |
| Drug class | Monoclonal antibody, Immune checkpoint inhibitor | Alkylating drug |
| Manufacturer | Regeneron Pharmaceuticals, Inc. and Sanofi | Pharma Mar, S.A. |
Efficacy
Libtayo (cemiplimab) Efficacy in Lung Cancer
Libtayo (cemiplimab) is a fully human monoclonal antibody that has been studied for its efficacy in treating certain types of lung cancer, specifically non-small cell lung cancer (NSCLC). It targets the immune checkpoint receptor PD-1 (programmed death-1) on T cells and has shown promise in improving outcomes for patients with advanced NSCLC. In clinical trials, Libtayo has demonstrated a significant improvement in overall survival compared to chemotherapy in patients with advanced NSCLC that expresses PD-L1 on at least 50% of tumor cells. The treatment has been particularly noted for its role in previously untreated patients, offering a new line of defense against this challenging disease.
Zepzelca (lurbinectedin) Efficacy in Lung Cancer
Zepzelca (lurbinectedin) is a newer cytotoxic chemotherapy agent that has been approved for the treatment of adults with metastatic small cell lung cancer (SCLC) that has progressed on or after platinum-based chemotherapy. Lurbinectedin works by binding to the DNA minor groove and inhibiting oncogenic transcription, leading to cell cycle arrest and apoptosis. In clinical studies, Zepzelca has shown efficacy in terms of overall response rate and duration of response in patients with relapsed SCLC, providing a valuable option for a population with limited treatment choices.
Both Libtayo and Zepzelca represent significant advancements in the treatment of different types of lung cancer. While Libtayo offers a new immunotherapeutic approach for NSCLC patients with high PD-L1 expression, Zepzelca provides a chemotherapeutic option for those with relapsed SCLC. The efficacy of these drugs in improving patient outcomes highlights the ongoing progress in lung cancer therapy and the importance of continued research and development in this field.
It is important to note that the efficacy of any medication can vary based on individual patient factors, and these treatments are not suitable for all lung cancer patients. As with any medication, the use of Libtayo and Zepzelca should be discussed with a healthcare professional who can consider the full context of a patient's medical history and the specific characteristics of their cancer.
Regulatory Agency Approvals
Libtayo
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
-
Health Canada
Zepzelca
-
Food and Drug Administration (FDA), USA
Access Libtayo or Zepzelca today
If Libtayo or Zepzelca are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us